



Dear future parents,

This is a very exciting time for you and it's only natural for you to be concerned about your baby's health. Your healthcare provider will help you to prepare for your baby's birth and will monitor your health and your baby's development. Doctors will explain the options for prenatal tests. Although most babies are born healthy, screening tests can detect certain genetic conditions. You may be offered a Non-Invasive Prenatal Test (NIPT), a new, safe and highly accurate method for checking genetic disorders such as Down syndrome.

In the past, prenatal testing choices were limited and sometimes stressful. You could choose between either screening tests with little risk for the baby but with limited accuracy, or "invasive" procedures with high accuracy but with a higher risk of miscarriage.

Nowadays, new Non-Invasive Prenatal Tests (NIPTs) are available that provide information of your baby's chance of having the most chromosomal abnormalities, such as Down syndrome.

Your decision to test may be influenced by how you feel about having a baby with these conditions. Talk to your doctor about NIPT tests.

What is Clarigo?

Clarigo is a safe, accurate and affordable Non-Invasive Prenatal Test (NIPT) that screens for the three most common chromosomal abnormalities:

- 1 Down syndrome (trisomy 21)
- 2 Edwards syndrome (trisomy 18)
- 3 Patau syndrome (trisomy 13)

Clarigo gives you and your doctor important information in the earliest stage of pregnancy and is more accurate than conventional screening methods. Clarigo helps you to avoid unnecessary, risky invasive procedures such as amniocentesis and chorionic villus sampling.

Down syndrome

The most common, well-known genetic abnormality is Down syndrome, caused by the presence of a third copy of chromosome 21. Approximately 22 in 10,000 babies are born with Down syndrome. It is associated with delayed physical development, typical facial features and mild to moderate intellectual disability.

Edwards syndrome

Edwards syndrome, also known as trisomy 18, is caused by an additional copy of chromosome 18. Edwards syndrome occurs in around one in every 6,000 pregnancies. Babies with this syndrome rarely survive due to abnormalities of the heart, kidneys and other internal organs.

Patau syndrome

Patau syndrome, also known as trisomy 13, is caused by an additional copy of chromosome 13. Like babies with trisomy 18, babies with trisomy 13 also have multiple birth defects and often don't survive the first few months.



Simple

Blood sample from the mother



Reliable

Screens for Down, Edwards and Patau syndrome



Safe

Risk-free for the pregnancy



Early pregnancy

As early as 8 weeks' gestation



Rapid

Results available within approximately one week



Accurate

Extensively validated and CE-Marked


How does Clarigo work?

Clarigo can be performed as early as 8 weeks' gestation. It poses no risk to you or to your baby. Clarigo requires a standard blood sample drawn from the mother's arm. The sample is sent to a local lab where an expert analyzes the DNA of the fetus for signs of trisomy of chromosomes 21, 18 and 13.

- **STEP 1**: The doctor draws a blood sample from the mother's arm. The blood sample contains cell-free DNA from the mother and the fetus.
- STEP 2: The blood sample is sent to the local laboratory and analyzed for:
 - 1. Down syndrome (trisomy 21)
 - 2. Edwards syndrome (trisomy 18)
 - 3. Patau syndrome (trisomy 13)
 - 4. Optionally, the gender of the fetus can be reported.
- **STEP 3**: The laboratory sends the test results to your doctor.
- **STEP 4**: Your doctor explains the results and provides counselling about further prenatal care.



What will Clarigo tell me?



What happens if Clarigo tests positive?

The result will help you and your doctor to decide if follow up testing is needed. Clarigo is a screening test and positive results should be confirmed by a diagnostic test such as a chorionic villus sampling or amniocentesis. Your doctor will advise you, give you the facts and discuss your options.





About Multiplicom

Multiplicom develops, manufactures and markets molecular diagnostic test kits which enable personalized treatment. Multiplicom N.V. was founded in 2011 as a spin-off from the University of Antwerp and VIB. The headquarters are based in Belgium.

For In Vitro Diagnostic Use.



Enabling personalized medicine